ICP-022 is a novel selective BTK inhibitor which is in clinical studies for efficacy and safety in a broad pivotal trials in China to treat B cell malignancies.
• BTK (Bruton Tyrosine Kinase) is a key molecule for signaling of B cell antigen receptor and cytokine receptor pathways. It is important for B cell activation, chemotaxis and adhesion through BCR pathways, and play a critical role for B cell proliferation, differentiation and apoptosis. Selective BTK inhibitors have been demonstrated effective for B cell malignancies and auto-immune diseases.
• B cell lymphoma is a leading hematological malignancy world-wide. ICP - 022 has excellent kinase selectivity in vitro and good anti-tumor activity in vivo.GLP tox study demonstrated good safety profile and large therapeutic window.